Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.